-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

Benzinga·10/05/2026 13:32:58
Listen to the news
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.